Post-Finasteride Syndrome Clinical Study Begins at Baylor College of Medicine

The Baylor College of Medicine (BCM) in Houston, Texas is the newest location for the next major clinic study to be funded by the Post-Finasteride Syndrome Foundation (PFS Foundation). Leading the study, which has been officially named the “Genetic and Epigenetic Studies on Post-Finasteride Syndrome Patients,” is Assistant Professor of Urology Dr. Mohit Khera. Dr. Khera is also the Director of the Laboratory for Andrology Research, McNair Medical Institute at BCM) and specializes in andrology, male reproductive medicine, and sexual wellness.

Post-Finasteride Syndrome is a medical condition that can significantly and adversely affect the quality of life for individuals who suffer from it, most often creating symptoms such as the loss of libido, impairment of cognitive functions, erectile dysfunction, Peyronie’s disease, muscle atrophy, penile shrinkage, severely dry skin, gynecomastia, and depression. Patients who suffer from Post-Finasteride Syndrome are often placed at significant risk of developing high-grade cancer. Common among those individuals who experience Post-Finasteride Syndrome are:

  • Undesirable effects to the patient’s sexual life
  • Significant changes to the patient’s quality of relationships
  • Difficult financial issues resulting from the patient’s job loss

The clinical study of Post-Finasteride Syndrome is the second of its kind; the first was initiated on July 1, 2013 and primarily focused on studying the symptomology of the illness. While the first study intended to identify the molecular patho-physiology of the syndrome, the second-round study will have a different objective. As identified by the PFS Foundation, the aim of the newest clinical study will be to determine the pathogenic mechanism behind the sexual dysfunction experienced by patients who consume Finasteride for the treatment of their prostate cancer (Proscar and generics) or management of their hair loss (Propecia and generics).

The need for a clinical study of Finasteride and the symptoms it can cause was sparked by the Food and Drug Administration’s (FDA) advisory to the drug manufacturer, Merck to revise the labeling on Propecia. Mounting evidence and statistical data supporting the evidence that consumption of Propecia could lead to persistent sexual dysfunction caught the FDA’s attention and prompted officials to review more than 400 cases of sexual dysfunction among users of Propecia. The FDA found that nearly 14% of patients reported sexual dysfunction, even after quitting the drug for 3 months.

Individuals involved in the new Post-Finasteride Syndrome clinical study strongly believe that even more promising results will be revealed during the Baylor College research that is being conducted by scientists and the university. If you or someone you know suffered adverse effects from the use of a Finasteride drug, please do not wait to seek legal help. At The Senators Firm, we handle defective drug cases of all natures, and we are prepared to take on your case next. Our experienced team of California defective drug attorneys is here to help you obtain maximum compensation for your pain and suffering. Call today to learn more.